As there is considerable preclinical and clinical evidence that both EGFR and ErbB2 play a central role in driving acquisition of antihormone resistance in breast cancer [12-19], it is possible that antihormones may actually play an active role in limiting their own activity through an ability to promote expression of these potent growth promoters. Here, ERBB2 is linked to breast cancer.